Table 1Selection Criteria

Criteria Description
Population Adult patients identified as iron deficient undergoing elective surgery (i.e., any surgery scheduled in

advance of the operation)

Intervention IV iron preparations (e.g., iron isomaltoside, ferric carboxymaltose, iron sucrose, ferumoxytol, iron dextran, sodium ferric gluconate)
Comparator Q1 to Q2: Blood transfusion, standard of care, saline, no treatment, no IV iron, placebo

Q3: No comparator

Outcomes Q1: Clinical Effectiveness (e.g., mortality and morbidity, length of hospital stay, comorbidities, need for blood transfusion, hemoglobin level, hemoglobin change, patient quality of life), safety (e.g., hypersensitivity, allergic reaction, rate of adverse events)

Q2: Cost-effectiveness (e.g., cost per quality-adjusted life-years gained, incremental cost. cost per adverse event avoided)

Q3: Recommendations related to the use of IV iron preparations for adult patients identified as iron deficient undergoing elective surgery

Study designs Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, economic evaluations, evidence-based guidelines

From: Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update

Cover of Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update
Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update: Rapid Review [Internet].
Hill S, Severn M; Authors.
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.